longevitywatch
Research · Interventions

AI model simulates a human cell from DNA to behavior

LongevityWatch editors · August 19, 2026 · 2 min

Simulating a cell on a computer has been a goal of biologists and computer scientists for decades. An AI startup has now announced a system that claims to simulate a human cell at every biological level, from DNA to whole-cell behavior. Whether it delivers on that promise remains to be independently verified.

GenBio AI, a company based in Palo Alto, unveiled AIDO Cell: a so-called world model of a cell. The system combines multiple AI models, each covering a different biological level. Together they aim to simulate how a cell responds to drugs or other interventions. An accompanying perspective piece appeared in Nature Medicine. Co-founders include Nobel laureate David Baker, known for his work in computational protein design.

How the system is built

The approach involves three stages. First, separate AI models are built for each biological layer: DNA, RNA, proteins. These models are then linked across layers. In the third stage, the entire network is optimized to function coherently as one system. Earlier AI models such as AlphaFold, which predicts protein structures from amino acid sequences, cover only a narrow slice of this hierarchy. The researchers aim to capture the full biological hierarchy in a single framework.

Baker himself noted that the system has not yet ‘solved’ cell biology. This is an early step. What is new is the integration of multiple biological scales into one framework, enabling researchers to ask computationally how an intervention at the DNA level propagates through to whole-cell behavior.

What this could mean for drug research

If such a virtual cell proves reliable, it could change how new compounds are tested. In principle, thousands of molecules could be screened computationally before any laboratory experiments, with only the most promising candidates tested in living cells. That would be both faster and less expensive.

For longevity science, the potential is similar: simulate what happens in an aging cell and test in silico which intervention corrects it most effectively. For now, however, this remains a vision. AIDO Cell has been announced, not independently validated.

Read the original article

Search terms for further reading: foundation model cell biology AI, in silico drug discovery, virtual cell simulation aging

What does the evidence say?
What are peptides and how do they work in the body?
Related research
18 Aug
Stem cell therapy shows promise but lacks consistency
18 Aug
Estrogen use linked to lower Alzheimer’s risk
16 Aug
New blood cancer pill opens a drug class
Newsletter

Stay in the loop

Twice a week, the most important longevity research in your inbox.